```

[Federal Register Volume 73, Number 3 (Friday, January 4, 2008)]
[Notices]
[Page 873]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 07-6270]

[[Page 873]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meetings

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of meetings of 
the National Cancer Institute Clinical Trials Advisory Committee.
    The meetings will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: National Cancer Institute Clinical Trials 
Advisory Committee, Ad Hoc Coordination Subcommittee.
    Date: February 3, 2008.
    Time: 7 p.m. to 9 p.m.
    Agenda: Discussion of the harmonization of SPORE, Cancer Center, 
and Cooperative Group Guidelines.
    Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 
Wisconsin Avenue, Bethesda, MD 20814.
    Contact Person: Sheila A. Prindiville, MD., Director, 
Coordinating Center for Clinical Trials, Office of the Director, 
National Cancer Institute, National Institutes of Health, 6120 
Executive Blvd., Suite 507, Bethesda, MD 20892, 301-451-5048, 
[email protected].

    Name of Committee: National Cancer Institute Clinical Trials 
Advisory Committee.
    Date: February 4, 2008.
    Time: 8 a.m. to 12 p.m.
    Agenda: Update on the progress of the implementation of the 
Clinical Trials Working Group.
    Place: National Institutes of Health, Building 31, 31 Center 
Drive, 6th Floor, Conference Room 10, Bethesda, MD 20892.
    Contact Person: Sheila A. Prindiville, MD., Director, 
Coordinating Center for Clinical Trials, Office of the Director, 
National Cancer Institute, National Institutes of Health, 6120 
Executive Blvd., Suite 507, Bethesda, MD 20892, 301-451-5048, 
[email protected].

    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    In the interest of security, NIH has instituted stringent 
procedures for entrance onto the NIH campus. All visitor vehicles, 
including taxicabs, hotel, and airport shuttles will be inspected 
before being allowed on campus. Visitors will be asked to show one 
form of identification (for example, a government-issued photo ID, 
driver's license, or passport) and to state the purpose of their 
visit.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: December 26, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 07-6270 Filed 1-3-08; 8:45 am]
BILLING CODE 4140-01-M
```